StreetAlpha.app
Home › Stocks › SRRK

Scholar Rock Holding Corp (SRRK)

Healthcare
$45.11
▲ +1.28%
LAST CLOSE · NOV 17

Scholar Rock develops antibody medicines that target myostatin for spinal muscular atrophy and other rare neuromuscular diseases. It last closed at $45.11 on Nov 17, up 1.28% on the day. SRRK last reported earnings on Tue, Nov 10, 2026. The average 12-month price target from 11 analysts is $71.55 (+58.6% from the last close), with a high of $84.00 and a low of $58.00. Analyst consensus is Strong Buy, based on the latest ratings from 11 firms (10 buy, 1 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $2.3M, the largest $2.3M.

AI Auto Pilots
Is SRRK in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$570K
Net income
−$413.6M
−72563.2% margin
EPS (diluted)
−$3.23
Free cash flow
−$309.9M
−54370.7% margin
Valuation
Market cap
$5.5B
122.0M shares
P/E
–
No P/E while losing money
Price to sales
9655.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$366.3M
At Sep 30
Debt
$196.2M
At Sep 30
Shareholder equity
$168.7M
Shares outstanding
122.0M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $18.8M$18.8MFY2021FY2022: $33.2M$33.2MFY2022FY2025: $0$0FY2025

From SRRK's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · Before the open (BMO)
Reported EPS
-$0.81
vs -$0.87 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±10.6%
Priced in before that report
Analyst consensus
Strong Buy
Based on 11 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
11firms
10 Buy1 Hold0 Sell
Each firm's latest rating on SRRK in the past 90 days
Average 12-month target
$71.55
▲ 58.6% upside

Based on 11 analysts who set a price target on SRRK in the past 90 days. The average target is $71.55, with a high of $84.00 and a low of $58.00, compared with the last close of $45.11.

Low $58.00Avg $71.55High $84.00
Blue marker: last close $45.11
Highest target$84.00
Average target$71.55
Lowest target$58.00
Latest rating changes
Truist SecuritiesTarget raised
Sep 24Buy$76 → $77
JP MorganTarget raised
Sep 21Buy$63 → $70
Evercore ISI GroupMaintained
Sep 15Buy$72
Piper SandlerTarget raised
Sep 15Buy$42 → $75
JefferiesMaintained
Sep 15Buy$65
DateFirmActionRatingPrice target
Sep 24Truist SecuritiesTarget raisedBuy$76 → $77
Sep 21JP MorganTarget raisedBuy$63 → $70
Sep 15Evercore ISI GroupMaintainedBuy$72
Sep 15Piper SandlerTarget raisedBuy$42 → $75
Sep 15JefferiesMaintainedBuy$65
Loading…

Technical Analysis

SRRK · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend

The stock sits between its 20 and 50 day averages. It is 7% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 50). The nearest support is the Pivot at $44.52, and the nearest resistance the swing high (Oct 29) at $45.19.

Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 5.3%/day
Key levels
$61.7652 week high+36.9%
$49.58100 day average+9.9%
$48.23200 day average+6.9%
$45.77Pivot R1+1.5%
$45.6750 day average+1.2%
$45.19Swing high (Oct 29)+0.2%
$45.11Last close
$44.52Pivot−1.3%
$44.4820 day average−1.4%
$43.87Pivot S1−2.7%
$43.23Swing low (Jun 11)−4.2%
$35.5352 week low−21.2%
Indicators
RSI (14)50.43Middle of its rangeNeutral
MACD0.12Above its signal lineBullish
Stochastic22.4Middle of its rangeNeutral
ADX (14)24.1Weak trend
Williams %R-74.6Oversold below −80, overbought above −20Neutral
CCI (20)4.3Oversold below −100, overbought above 100Neutral
Rate of change+2.6%Change over 10 sessionsBullish
ATR (14)$2.40Typical daily range, 5.3% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for SRRK

What happened before

See how SRRK did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow SRRK usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How SRRK has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in SRRK in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$2.3M
Largest print
$2.3M
Loading…

SRRK Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲186 buying vs 127 selling
  • ▲Held by funds +5.6 pts
  • ●Funds holding +3
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding311308+1.0%
In funds' top 10106+66.7%
Held by funds119.3%113.7%+5.6 pts
New / increased49 / 13755 / 129+1.1%
Reduced / sold out84 / 4382 / 21+23.3%
Put/call ratio1.722.22−22.6%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SRRK institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SRRK is in one of them and how their past SRRK trades turned out.

SRRK in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SRRK in an article yet. Here's the latest on the wider market.

About Scholar Rock Holding

Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts. It develops antibody medicines for people with spinal muscular atrophy (SMA) and other rare, severe neuromuscular diseases. Its lead product candidate, apitegromab, blocks myostatin, a protein that limits muscle growth, and is being studied in SMA and facioscapulohumeral muscular dystrophy. The company is also developing a subcutaneous form of apitegromab and is seeking regulatory approval in the United States and Europe.

Headquarters
Cambridge, MA